Subscribe 
Hydra Biosciences Inc
Hydra Biosciences Inc
Develops medicines and drugs targeting ion channels.
| Year Established: | |
| Funding: | 22 |
| Address: | Hydra Biosciences, Inc. 790 Memorial Drive, off Pleasant Street Cambridge, MA 02139 |
| Telephone: | 2147483647 |
| Mobile: | |
| Fax: | 6174945245 |
| Mail: | info@hydrabiosciences.com |
| Company URL: | http://www.hydrabiosciences.com |
blocks_tabs
Thank you for your interest in Hydra Biosciences. We are always seeking talented people who are looking for a challenging and rewarding work experience. Please send your resume to jobs@hydrabiosciences.com. Openings can become available at any time.
- October 19, 2009
Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management - May 18, 2009
Research published in PNAS by Hydra Biosciences is First Demonstration in Mammals that TRP Ion Channel Drug Can Treat Allergy-Induced Asthma - January 20, 2009
Emerging Drug Developer: Hydra Biosciences (FierceBiotech) - January 16, 2009
Hydra Brings in $22M in Series D to Push First Program into Clinic (BioWorld Today) - January 16, 2009
Hydra Biosciences Reaps $22.2M Series D (Dow Jones VentureWire) - January 16, 2009
Hydra Biosciences Raises $22M to Create New Pain Relievers With Fewer Side Effects (Xconomy) - January 16, 2009
Hydra garners $22M for ion channel programs (FierceBiotech) - January 16, 2009
Hydra Biosciences Raises $22 Million in Series D Financing - October 24, 2008
Hydra Biosciences Bolsters Discovery and IP Capabilities with Key Additions to Executive Management Team - January 2, 2008
Hydra Biosciences CEO Russell Herndon Interviewed on NECN (QuickTime movie, 7 MB) - November 16, 2007
Hydra Biosciences Featured in Mass High Tech Article - August 14, 2007
Hydra Biosciences Publishes Article in PNAS Demonstrating that TRPA1 Mediates Formalin-Induced Pain - August 7, 2007
Hydra Biosciences Announces Data Revealing the Crucial Role Played by the TRPA1 Ion Channel in a Standard Model of Pain Receptor Activation - July 26, 2007
Hydra Biosciences and Pfizer Global Research & Development Sign Collaboration Agreement - April 25, 2006
Hydra Biosciences Co-founder Dr. David Clapham Elected to the National Academy of Sciences - January 26, 2006
Regeneration Sans Stem Cells - January 5, 2006
Hydra Biosciences Appoints Russell H. Herndon as Chief Executive Officer - April 1, 2005
Sophion and Hydra Establish a Unique Reference Site for QPatch Automated Patch Clamp System - April 26, 2004
Hydra Biosciences Co-founder Dr. Mark Keating Elected to the National Academy of Sciences - January 12, 2004
Hydra Biosciences Raises $18.875 Million in Series B Financing - December 4, 2003
Hydra Biosciences Appoints Glenn R. Larsen, Ph.D. as Chief Scientific Officer - November 2003
Regrow Your Own - Broken heart? No problem. New liver? Coming right up. The road to regeneration starts here. - July 25, 2002
Hydra Biosciences, a Biopharmaceuticals Company Developing Molecular Regeneration Medicines, Secures $10 Million in Series A Funding
Advanced Technology Ventures,BioVentures Investors,Polaris Venture Partners
Glenn Larsen
Chief Operating Officer and Executive Vice President of Development
Russell Herndon
President and Chief Executive Officer
Tom Burke
Vice President of Finance and Treasurer
David Kimball
Chief Scientific Officer